Johnson & Johnson $JNJ Shares Sold by Swedbank AB

Key Points

• Swedbank AB has reduced its ownership in Johnson & Johnson by 4.1%, selling 86,007 shares and now holds approximately 2,008,649 shares worth $306,821,000.
• Johnson & Johnson recently reported a Q2 earnings per share of $2.77, surpassing analysts' estimates and indicating a 5.8% increase year-over-year in revenue.
• The company declared a quarterly dividend of $1.30 per share, which reflects an annualized yield of 2.9% with a payout ratio of 55.61%.

Swedbank AB lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,008,649 shares of the company's stock after selling 86,007 shares during the quarter. Swedbank AB owned about 0.08% of Johnson & Johnson worth $306,821,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Secure Asset Management LLC increased its holdings in Johnson & Johnson by 8.2% in the 2nd quarter. Secure Asset Management LLC now owns 4,981 shares of the company's stock worth $761,000 after buying an additional 377 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 563,634 shares of the company's stock worth $86,095,000 after purchasing an additional 27,567 shares during the period. Brooklyn FI LLC grew its stake in shares of Johnson & Johnson by 4.7% during the 2nd quarter. Brooklyn FI LLC now owns 2,098 shares of the company's stock worth $320,000 after purchasing an additional 94 shares during the period. Sovran Advisors LLC grew its stake in shares of Johnson & Johnson by 7.2% during the 2nd quarter. Sovran Advisors LLC now owns 6,323 shares of the company's stock worth $985,000 after purchasing an additional 422 shares during the period. Finally, Financial Management Network Inc. grew its stake in shares of Johnson & Johnson by 12.8% during the 2nd quarter. Financial Management Network Inc. now owns 3,015 shares of the company's stock worth $470,000 after purchasing an additional 341 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock traded up $1.81 during midday trading on Friday, reaching $175.97. The stock had a trading volume of 25,617,065 shares, compared to its average volume of 8,957,862. The company's fifty day simple moving average is $172.42 and its 200 day simple moving average is $161.62. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $423.80 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $177.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.